ArticleJTO clinical and research reports2025

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292).

Rachel E Reingold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.